PecFent

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
04-04-2024
Ciri produk Ciri produk (SPC)
04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
03-08-2018

Bahan aktif:

fentanyl

Boleh didapati daripada:

Kyowa Kirin Holdings B.V.

Kod ATC:

N02AB03

INN (Nama Antarabangsa):

fentanyl

Kumpulan terapeutik:

Analgesics

Kawasan terapeutik:

Pain; Cancer

Tanda-tanda terapeutik:

PecFent is indicated for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equi-analgesic dose of another opioid for a week or longer.

Ringkasan produk:

Revision: 23

Status kebenaran:

Authorised

Tarikh kebenaran:

2010-08-31

Risalah maklumat

                                38
B. PACKAGE LEAFLET
39
PACKAGE LEAFLET: INFORMATION FOR THE USER
PECFENT 100 MICROGRAMS/SPRAY NASAL SPRAY, SOLUTION
PECFENT 400 MICROGRAMS/SPRAY NASAL SPRAY, SOLUTION
fentanyl
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctoror pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What PecFent is and what it is used for
2.
What you need to know before you use PecFent
3.
How to use PecFent
4.
Possible side effects
5.
How to store PecFent
6.
Contents of the pack and other information
1.
WHAT PECFENT IS AND WHAT IT IS USED FOR
WHAT PECFENT IS
PecFent contains fentanyl, which is a strong pain-relieving medicine
known as an opioid pain killer.
WHAT PECFENT IS USED FOR
PecFent is used in adults with cancer for a type of pain called
‘breakthrough’ pain.
•
Breakthrough pain comes on suddenly.
•
It comes on even though you have taken your usual opioid pain killer
(such as morphine,
fentanyl, oxycodone or hydromorphone) to control your constant
background pain.
PecFent is only to be used by adults who are already taking other
opioid medicines daily for their
constant cancer pain.
HOW PECFENT WORKS
PecFent is a nasal spray, solution
•
When you spray PecFent into your nose the very small spray droplets
form a thin gel.
•
Fentanyl is absorbed quickly through the lining of your nose and into
the blood stream.
•
This means the medicine gets into your system quickly to relieve your
breakthrough pain.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE PECFENT
DO NOT USE PECFENT IF:
•
you are allergic to fentanyl or any of the other ingredients of this
medicine (
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
PecFent 100 micrograms/spray nasal spray, solution
PecFent 400 micrograms/spray nasal spray, solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
PecFent 100 micrograms/spray nasal spray, solution
Each ml of solution contains 1,000 micrograms fentanyl (as citrate)
1 spray (100 microlitres) contains 100 micrograms fentanyl (as
citrate)
Bottles contain:
0.95 ml (950 micrograms fentanyl) -
2 spray bottle
or
1.55 ml (1,550 micrograms fentanyl) - 8 spray bottle
PecFent 400 micrograms/spray nasal spray, solution
Each ml of solution contains 4,000 micrograms fentanyl (as citrate)
1 spray (100 microlitres) contains 400 micrograms fentanyl (as
citrate)
Each bottle contains 1.55 ml (6,200 micrograms fentanyl)
Excipients with known effect:
_ _
Each spray contains 0.02 mg propylparahydroxybenzoate (E216).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Nasal spray, solution (nasal spray).
A clear to practically clear colourless aqueous solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
PecFent is indicated for the management of breakthrough pain (BTP) in
adults who are already
receiving maintenance opioid therapy for chronic cancer pain.
Breakthrough pain is a transitory
exacerbation of pain that occurs on a background of otherwise
controlled persistent pain.
Patients receiving maintenance opioid therapy are those who are taking
at least 60 mg of oral
morphine daily, at least 25 micrograms of transdermal fentanyl per
hour, at least 30 mg of oxycodone
daily, at least 8 mg of oral hydromorphone daily or an equianalgesic
dose of another opioid for a week
or longer.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment should be initiated by and remain under the supervision of a
physician experienced in the
management of opioid therapy in cancer patients. Physicians should
keep in mind the potential for
abuse of fentanyl.
3
Posology
PecFent should be titrated to an “effective” dose that provides
adequate anal
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 04-04-2024
Ciri produk Ciri produk Bulgaria 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 03-08-2018
Risalah maklumat Risalah maklumat Sepanyol 04-04-2024
Ciri produk Ciri produk Sepanyol 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 03-08-2018
Risalah maklumat Risalah maklumat Czech 04-04-2024
Ciri produk Ciri produk Czech 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Czech 03-08-2018
Risalah maklumat Risalah maklumat Denmark 04-04-2024
Ciri produk Ciri produk Denmark 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 03-08-2018
Risalah maklumat Risalah maklumat Jerman 04-04-2024
Ciri produk Ciri produk Jerman 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 03-08-2018
Risalah maklumat Risalah maklumat Estonia 04-04-2024
Ciri produk Ciri produk Estonia 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 03-08-2018
Risalah maklumat Risalah maklumat Greek 04-04-2024
Ciri produk Ciri produk Greek 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Greek 03-08-2018
Risalah maklumat Risalah maklumat Perancis 04-04-2024
Ciri produk Ciri produk Perancis 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 03-08-2018
Risalah maklumat Risalah maklumat Itali 04-04-2024
Ciri produk Ciri produk Itali 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Itali 03-08-2018
Risalah maklumat Risalah maklumat Latvia 04-04-2024
Ciri produk Ciri produk Latvia 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 03-08-2018
Risalah maklumat Risalah maklumat Lithuania 04-04-2024
Ciri produk Ciri produk Lithuania 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 03-08-2018
Risalah maklumat Risalah maklumat Hungary 04-04-2024
Ciri produk Ciri produk Hungary 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 03-08-2018
Risalah maklumat Risalah maklumat Malta 04-04-2024
Ciri produk Ciri produk Malta 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Malta 03-08-2018
Risalah maklumat Risalah maklumat Belanda 04-04-2024
Ciri produk Ciri produk Belanda 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 03-08-2018
Risalah maklumat Risalah maklumat Poland 04-04-2024
Ciri produk Ciri produk Poland 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Poland 03-08-2018
Risalah maklumat Risalah maklumat Portugis 04-04-2024
Ciri produk Ciri produk Portugis 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 03-08-2018
Risalah maklumat Risalah maklumat Romania 04-04-2024
Ciri produk Ciri produk Romania 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Romania 03-08-2018
Risalah maklumat Risalah maklumat Slovak 04-04-2024
Ciri produk Ciri produk Slovak 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 03-08-2018
Risalah maklumat Risalah maklumat Slovenia 04-04-2024
Ciri produk Ciri produk Slovenia 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 03-08-2018
Risalah maklumat Risalah maklumat Finland 04-04-2024
Ciri produk Ciri produk Finland 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Finland 03-08-2018
Risalah maklumat Risalah maklumat Sweden 04-04-2024
Ciri produk Ciri produk Sweden 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 03-08-2018
Risalah maklumat Risalah maklumat Norway 04-04-2024
Ciri produk Ciri produk Norway 04-04-2024
Risalah maklumat Risalah maklumat Iceland 04-04-2024
Ciri produk Ciri produk Iceland 04-04-2024
Risalah maklumat Risalah maklumat Croat 04-04-2024
Ciri produk Ciri produk Croat 04-04-2024
Laporan Penilaian Awam Laporan Penilaian Awam Croat 03-08-2018

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen